Personalis rises as Medicare extends coverage to lung cancer test

Personalis

10/02/2026 11:43

** Shares of U.S.-based cancer diagnostics firm Personalis PSNL.O rise 2.3% to $8.01 premarket

**  Co says Medicare will now cover its NeXT Personal test for monitoring early-stage non-small cell lung cancer, the most common form of the disease

** Says the test tracks tiny bits of circulating tumor DNA (ctDNA) in blood that can indicate the presence of cancer; analyzes hundreds of tumor-specific mutations to guide ongoing care decisions

** Move follows Medicare approval for the same test in breast cancer patients, co says

** Medicare is the U.S. government health insurance program for people aged 65 and older

** Shares rose ~38% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))